Kinnate Zeroes In On BRAF Subpopulation For Exarafenib Development Strategy

BeiGene And Partners Present RAF Dimer Inhibitor Data

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Kinnate presented early monotherapy and combination data for its pan-RAF inhibitor at AACR, but its prioritization of BRAF Class II drew analyst concerns that its focus might be too narrow.

Kinnate presented Phase I data for its pan-RAF inhibitor, exarafenib • Source: Shutterstock

Kinnate Biopharma, Inc. is putting the bulk of its initial energy into certain patients with non-small cell lung cancer (NSCLC) and melanoma in developing the pan-RAF inhibitor exarafenib as a monotherapy, while at least initially putting less of an emphasis on other patient populations, a strategy that drew concern from an analyst that it would narrow the drug’s market opportunity.

The company presented early data from its Phase I study of exarafenib at the American Association for Cancer Research meeting...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.